Conditions: Hepatitis C Virus
Keywords: Hepatitis C Genotype 4 Hepatitis C Chronic Hepatitis C Hepatitis C Genotype 6 Hepatitis C Genotype 5
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 121
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the effect of response to treatment by evaluating the percentage of subjects achieving a 12-week sustained virologic response (SVR12) after 12 weeks of treatment with ABT-493/ABT-530 and to evaluate the safety of the regimen in participants with chronic hepatitis C virus (HCV) genotype (GT) 4, 5, or 6 infection.

Detailed description:

Arms:
arm 1: ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.

Interventions: intervention 1: ABT-493/ABT-530
Intervention descriptions: intervention 1: Tablet; ABT-493 coformulated with ABT-530

Protocol document: